Hait and Libutti in conversation; Rutgers Cancer Institute founder and its current director talk history

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Steven K. Libutti, MD, FACS

Steven K. Libutti, MD, FACS

Director, Rutgers Cancer Institute of New Jersey
Senior vice president of oncology services, RWJBarnabas Health; Vice chancellor for cancer programs, Rutgers Biomedical and Health Sciences; Professor of surgery, Rutgers Robert Wood Johnson Medical School; Affiliated Distinguished Professor in Genetics, Rutgers School of Arts and Sciences.
William N. Hait, MD, PhD

William N. Hait, MD, PhD

Global Head, Johnson & Johnson External Innovation.

In 1993, when William Hait came to New Jersey to start work toward the NCI designation for Rutgers, the place had one office and three cubicles.

Four years later, in 1997, the Cancer Institute of New Jersey received the NCI Cancer Center designation, and on the next review cycle, in 2002, it received the Comprehensive Cancer Center designation.

The Cancer History Project invited Hait, the first director of Rutgers Cancer Institute of New Jersey to sit down for a conversation with Steven K. Libutti, the institution’s current director.

“That’s almost unprecedented today, to be able to achieve that, and so, that’s an amazing accomplishment,” Libutti said to Hait.

How did Hait get it done? 

“I was given some very sound advice from my colleagues at Yale. They said, ‘Your instinct will be to build the basic science programs first.’ They said, ‘Build the clinical programs first, because that’s what the center at first will be known for.’

“So, I tried my best to recruit outstanding clinical people, clinical researchers, master clinicians, people who could really be dedicated to giving incredibly high-level care to the people in New Jersey.”

Rutgers, now a part of a health system and a scientific consortium with Princeton University, recently started construction of a $750 million cancer hospital in collaboration with RWJBarnabas Health.

Table of Contents

YOU MAY BE INTERESTED IN

The University of California, San Francisco and global oncology communities mourn the death of Felix Y. Feng, MD, a radiation oncologist and a leading figure in genitourinary cancer research. A professor of radiation oncology, urology and medicine, and vice chair of translational research at the UCSF Helen Diller Family Comprehensive Cancer Center, Feng died from cancer on Dec.10, 2024. He was 48.
The late Felix Feng, MD (center) with researchers Jonathan Chou, MD, PhD (left) and Lisa Chesner, PhD (right), in 2019.Photo by Noah BergerFelix Y. Feng, a genitourinary cancer research leader, died on Dec. 10, 2024. He was 48.This article is republished with permission by NRG Oncology.Dr. Feng was the former NRG Oncology Genitourinary Cancer Committee chair and an RTOG Foundation member. After years of dedicated and enthusiastic commitment to the NRG and previously the RTOG Genitourinary Cancer Committee, chairing or co-chairing 13 research protocols for NRG and RTOG, Dr. Feng was appointed committee chair in March 2018, following in the footsteps of Dr. Howard Sandler, his mentor. Dr. Feng was also a member of the RTOG Foundation Board of Directors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login